MAPK3 and melanoma: We also found that the pharmacological targeting of the MAPK signaling pathway via IGF1R and ERK1/2 inhibitors was able to partially restore the sensitivity of HAT1-knockdown and HAT1-KO melanoma cells to BRAFi.